Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Reference
Endpoint:
dermal absorption in vitro / ex vivo
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
secondary literature
Justification for type of information:
The dermal absorption factor is reported from a regulatory opinion document from the Scientific Committee on Consumer Products (SCCP). The dermal absorption factor considered in this opinion is used to determine the Margin of Safety (MoS) of 4-methylbenzylidene camphor in sunscreens.
Qualifier:
according to guideline
Guideline:
OECD Guideline 428 (Skin Absorption: In Vitro Method)
Version / remarks:
1994, draft
Qualifier:
according to guideline
Guideline:
other: COLIPA Guideline for Percutaneous Absorption/Penetration
Version / remarks:
1995
GLP compliance:
not specified
Remarks:
Study is summarised in a regulatory opinion document; full study details are not available
Radiolabelling:
no
Species:
pig
Sex:
female
Type of coverage:
not specified
Duration of exposure:
24 hours
Doses:
167 to 200 μg test item/cm², corresponding to 4.5 mg formulation/cm² of a 4% test item formulation
No. of animals per group:
8 experiments, performed in triplicate
Details on study design:
SAMPLE COLLECTION
- Skin surface: Gentle scraping with a spatula and/or threefold wiping with cotton wool (corresponds to non-absorbed sample)
- Horny layer: About 15-20 fold stripping with self-adhesive "tesa-film" tape
- Epidermis: Heating of the skin disc (epidermal side for 45 seconds on a 80°C hot plate (Ceram), separation epidermis from dermis with forceps)
- Dermis: 3 punched samples or total dermis
- Receptor fluid: 2 aliquots

ANALYSIS
- Method type(s) for identification: HPLC-DAD
- Limits of detection and quantification: LOD: approximately 0.03 μg/mL, LOQ: approximately 0.1 μg/mL
Details on in vitro test system (if applicable):
SKIN PREPARATION
- Source of skin: Pig
- Type of skin: Unboiled back skin
- Preparative technique: Skin discs (gently dry-shaved surface, diameter 5 cm)
- Thickness of skin: 3-4 mm

PRINCIPLES OF ASSAY
- Diffusion cell: Glass penetration cell
- Receptor fluid: 0.9% sodium chloride, 1% bovine serum albumin and 0.02% gentamycine sulphate in water
- Solubility of test substance in receptor fluid: Receptor fluid suitable for hydrophilic and lipophilic samples
- Test temperature: 32°C
Signs and symptoms of toxicity:
not specified
Dermal irritation:
not specified
Absorption in different matrices:
No test item was detected in the receptor fluid.
Total recovery:
Mean total recovery was 91.8% (range 86.8 to 95.6%).
Key result
Time point:
24 h
Dose:
178 μg/cm²
Parameter:
percentage
Remarks:
1.96 μg/cm² (epidermis+dermis)
Absorption:
1.1 %
Remarks on result:
other: mean of 8 experiments

Table 1. Summary of dermal absorption rates

 Test  Applied substance (μg/cm²)  Surface (μg/cm²)  Horny layer (μg/cm²)  Epidermis (μg/cm²)  Dermis (μg/cm²)  Recovery (%)
 1  182  125  38.2  2.0  0.34  90.9
 2  200  159  26.2  1.3  0.50  93.8
 3  172  132  27.6  2.4  0.72  94.7
 4  175  119  31.0  1.7  0.90  87.2
 5  171  138  23.5  0.7  0.34  95.0
 6  167  132  16.2  1.4  0.88  90.0
 7  187  144  17.1  0.4  not detectable  86.8
 8  173  140  23.5  2.2  not detectable  95.6
 Mean  178  136  25.4  1.5  0.46  91.8
 Standard deviation  11  12.5  7.2  0.7  0.36  3.5
Conclusions:
Taking into account the values obtained in eight separate experiments, the SCCP consider a mean dermal absorption value of 1.96 μg/cm² as the basis to determine safe use for 4-methylbenzylidene camphor in sunscreen formulations. Based on a mean applied amount of 178 μg/cm², the dermal absorption factor is calculated to be 1.10% (epidermis+dermis).
Executive summary:

Data on the dermal absorption of 4 -methylbenzylidene camphor is available in a regulatory opinion document from the Scientific Committee on Consumer Products (SCCP). Taking into account the values obtained in eight separate in vitro experiments using pig skin, the SCCP consider a mean dermal absorption value of 1.96 μg/cm² as the basis to determine safe use for 4-methylbenzylidene camphor in sunscreen formulations. Based on a mean applied amount of 178 μg/cm², the dermal absorption factor is calculated to be 1.10% (epidermis+dermis). The reliability of this data source cannot be assigned (Klimisch 4) as it is a secondary source reporting from a summary of eight individual experiments. The original studies were not obtained for reliability and relevance assessment, however as the data is used in a regulatory opinion, it is assumed to be sufficiently reliable.

Description of key information

In a study by Schauer et al (2006), plasma levels and toxicokinetics were investigated in both human subjects and rats following dermal exposure:

The toxicokinetics of 4-methylbenzylidene camphor after dermal administration were investigated in humans. Humans (3 male and 3 female subjects) were exposed to 4-MBC by topical application of a commercial sunscreen formulation containing 4% 4-MBC (w/w), covering 90% of the body surface and resulting in a mean dermal 4-MBC dose of 22 mg/kg bw. Concentrations of 4-MBC and its metabolites were monitored over 96 h in plasma and urine. Peak plasma levels (Cmax) of 4-MBC were reached 6 h after dermal application (200 pmol/mL in males and 100 pmol/mL in females). After the 6 h sampling point, 4-MBC concentrations decreased following 1st order kinetics with a half-life of 9 h to reach the limit of quantitation at 48 h (males) or 36 h (females) after the application. The AUC values were 3884 and 1909 pmol/mL h in males and females, respectively. In plasma, 3-(4-carboxybenzylidene)camphor is the major metabolic product, whereas, in urine, 3-(4-carboxybenzylidene)-6-hydroxycamphor and a glucuronide of 3-(4-carboxybenzylidene)camphor are major metabolites. Less than 1% of the applied dose of 4-MBC was recovered in urine as metabolites.

The toxicokinetics of 4-methylbenzylidene camphor after dermal administration were investigated in rats. Wistar rats (3 male and 3 female subjects) were exposed to dermal 4-MBC doses of 400 and 2000 mg/kg bw applied in a formulation using an occlusive patch for 24 h. Concentrations of 4-MBC and its metabolites were monitored over 96 h in plasma. Peak plasma levels of 4-MBC were 200 (dose of 400 mg/kg bw) and 1200 pmol/mL (dose of 2000 mg/kg bw) in male and female rats. These levels remained constant for up to 24–48 h after dermal application. Two major metabolites were identified in the plasma of rats after dermal application: 3-(4-carboxybenzylidene)-6-hydroxycamphor and 3-(4-carboxybenzylidene)camphor.

In an opinion document on 4-MBC by the Scientific Committee on Consumer Products (SCCP, 2008) a toxicokinetic approach was used to derive a Margin of Safety (MoS) for 4-MBC. A mean dermal absorption value of 1.96 μg/cm² from an applied substance amount of 178 μg/cm² yielded a calculated dermal absorption value of 1.10%.

Key value for chemical safety assessment

Absorption rate - oral (%):
50
Absorption rate - dermal (%):
1.1
Absorption rate - inhalation (%):
100

Additional information

The study by Schauer et al. (2006) concluded that the biotransformation of 4-MBC in humans and rats after dermal administration is identical and occurs by a series of cytochrome P450-catalyzed oxidations of 4-MBC followed by formation of glucuronides. Also the kinetics following dermal exposure to 4-MBC was considered to be similar between rats and humans with peak plasma levels being reached approximately 6 hours following the exposure and plasma levels regressing towards the limit of quantification at around 48 hours post-exposure. As no new dermal absorption studies have been identified with adequate reliability, a dermal absorption factor of 1.10% is used in line with the current regulatory opinion (SCCP 2008).